Regeneron, Sanofi Get CHMP Backing for Dupixent in Children With Severe Atopic Dermatitis
October 16 2020 - 8:51AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said the
European Medicines Agency's Committee for Medicinal Products for
Human Use recommended expanded approval of Dupixent to treat
children with severe atopic dermatitis.
The companies said the recommendation covers the treatment of
patients ages six to 11 years with severe atopic dermatitis who are
candidates for systemic therapy.
The European Commission, which generally follows the CHMP's
advice, is expected to announce a final decision in the coming
months, the companies said.
Dupixent is already approved for the treatment of uncontrolled
moderate-to-severe atopic dermatitis for people 12 years of age and
older in the EU and six years of age and older in the U.S.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it
jointly in the U.S. with France's Sanofi under a 2007 collaboration
agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 16, 2020 08:36 ET (12:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2023 to Sep 2024